A molecular link between the active component of marijuana and Alzheimer's disease pathology.

Alzheimer's disease is the leading cause of dementia among the elderly, and with the ever-increasing size of this population, cases of Alzheimer's disease are expected to triple over the next 50 years. Consequently, the development of treatments that slow or halt the disease progression have become imperative to both improve the quality of life for patients and reduce the health care costs attributable to Alzheimer's disease. Here, we demonstrate that the active component of marijuana, Delta9-tetrahydrocannabinol (THC), competitively inhibits the enzyme acetylcholinesterase (AChE) as well as prevents AChE-induced amyloid beta-peptide (Abeta) aggregation, the key pathological marker of Alzheimer's disease. Computational modeling of the THC-AChE interaction revealed that THC binds in the peripheral anionic site of AChE, the critical region involved in amyloidgenesis. Compared to currently approved drugs prescribed for the treatment of Alzheimer's disease, THC is a considerably superior inhibitor of Abeta aggregation, and this study provides a previously unrecognized molecular mechanism through which cannabinoid molecules may directly impact the progression of this debilitating disease.

[1]  C. Lanni,et al.  Acetylcholinesterase inhibitors: novel activities of old molecules. , 2004, Pharmacological research.

[2]  D. Kildea,et al.  Is senile dementia "age-related" or "ageing-related"? —evidence from meta-analysis of dementia prevalence in the oldest old , 1995, The Lancet.

[3]  J F Stoltz,et al.  Molecular rotors as fluorescent probes for biological studies. , 1998, Clinical hemorheology and microcirculation.

[4]  M. L. de Ceballos,et al.  Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation , 2005, The Journal of Neuroscience.

[5]  B. P. Doctor,et al.  Stable Complexes Involving Acetylcholinesterase and Amyloid-β Peptide Change the Biochemical Properties of the Enzyme and Increase the Neurotoxicity of Alzheimer’s Fibrils , 1998, The Journal of Neuroscience.

[6]  S. Bachurin.  Medicinal chemistry approaches for the treatment and prevention of Alzheimer's disease , 2003, Medicinal research reviews.

[7]  J. P. Kennedy,et al.  Evaluation of "credit card" libraries for inhibition of HIV-1 gp41 fusogenic core formation. , 2006, Journal of combinatorial chemistry.

[8]  N. Milton.  Anandamide and noladin ether prevent neurotoxicity of the human amyloid-β peptide , 2002, Neuroscience Letters.

[9]  A. Olson,et al.  Discovery of acetylcholinesterase peripheral anionic site ligands through computational refinement of a directed library. , 2005, Biochemistry.

[10]  N. Inestrosa,et al.  Thioflavin T Is a Fluorescent Probe of the Acetylcholinesterase Peripheral Site That Reveals Conformational Interactions between the Peripheral and Acylation Sites* , 2001, The Journal of Biological Chemistry.

[11]  S. Moore,et al.  The peripheral anionic site of acetylcholinesterase: structure, functions and potential role in rational drug design. , 2006, Current pharmaceutical design.

[12]  M. Herkenham,et al.  International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors , 2002, Pharmacological Reviews.

[13]  K. Beyreuther,et al.  A4 Protein in Alzheimer's Disease: Primary and Secondary Cellular Events in Extracellular Amyloid Deposition , 1989, Journal of neuropathology and experimental neurology.

[14]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[15]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[16]  V. Andrisano,et al.  beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. , 2003, Biochemical pharmacology.

[17]  A. Cavalli,et al.  3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. , 2003, Journal of medicinal chemistry.

[18]  J. Romero,et al.  Role of the endocannabinoid system in Alzheimer's disease: new perspectives. , 2004, Life sciences.

[19]  H. Levine,et al.  Thioflavine T interaction with synthetic Alzheimer's disease β‐amyloid peptides: Detection of amyloid aggregation in solution , 1993, Protein science : a publication of the Protein Society.

[20]  D. Evans,et al.  Estimated prevalence of Alzheimer's disease in the United States. , 1990, The Milbank quarterly.

[21]  E. Carlini.  The good and the bad effects of (−) trans-delta-9-tetrahydrocannabinol (Δ9-THC) on humans , 2004 .

[22]  A. Cavalli,et al.  Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase-induced beta-amyloid aggregation. , 2005, Journal of medicinal chemistry.

[23]  A. Izzo,et al.  Neuroprotective effect of cannabidiol, a non‐psychoactive component from Cannabis sativa, on β‐amyloid‐induced toxicity in PC12 cells , 2004, Journal of neurochemistry.

[24]  P. Vogt,et al.  A credit-card library approach for disrupting protein-protein interactions. , 2006, Bioorganic & medicinal chemistry.

[25]  Alberto Rábano,et al.  Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains , 2003, The Journal of Neuroscience.

[26]  R. Mechoulam,et al.  Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish , 1964 .

[27]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.

[28]  T. Rosenberry,et al.  Nonequilibrium analysis alters the mechanistic interpretation of inhibition of acetylcholinesterase by peripheral site ligands. , 1998, Biochemistry.

[29]  Claudia Linker,et al.  Acetylcholinesterase Accelerates Assembly of Amyloid-β-Peptides into Alzheimer's Fibrils: Possible Role of the Peripheral Site of the Enzyme , 1996, Neuron.